Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure

Cancer Investigation

Volumn 23, Issue 5, 2005, Pages 386-391

  Demiray, Mutlu ^a   Kurt, Ender ^a   Evrensel, Turkkan ^a   Kanat, Ozkan ^a   Arslan, Murat ^a   Saraydaroglu, Ozlem ^a   Ercan, Ilker ^a   Gonullu, Guzin ^a   Gokgoz, Sehsuvar ^a   Topai, Ugur ^a   Tolunay, Sahsine ^a   Tasdelen, Ismet ^a   Manavoglu, Osman ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Gemcitabine; Metastatic breast cancer; Paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TREATMENT OUTCOME;

EID: 24944535246     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-67133     Document Type: Article

References (28)

1. Bergh, J.; Jonsson, P.E.; Glimelius, B.; Nygren, P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001, 40 (2-3), 253-281.
2. Hortobagyi, G.N. Treatment of breast cancer. N. Engl. J. Med. 1998, 339 (14), 974-984.
3. Crown, J.; Dieras, V.; Kaufmann, M.; von Minckwitz, G.; Kaye, S.; et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol. 2002, 3 (12), 719-727.
4. Tripathy, D. Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin. Breast Cancer 2002, 3 (Suppl. 1), 8-11.
5. Blackstein, M.; Vogel, C.L.; Ambinder, R.; Cowan, J.; Iglesias, J.; Melemed, A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002, 62 (1), 2-8.
6. Possinger, K.; Kaufmann, M.; Coleman, R.; Stuart, N.S.; et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-Cancer Drugs 1999, 10 (2), 155-162.
7. Gerson, R.; Serrano-O, A.; Villalobos, A.; Ortiz, C.; Sánchez-Forgach, E. In Gemcitabine response in advanced breast cancer in relation to ýmmunohistochemical factors. Proceedings of the American Society of Clinical Oncology Annual Meeting, New Orleans, USA, May 20-23, 2000; American Society of Clinical Oncology: Alexandria, 2000; 145a.
8. Spielmann, M.; Llombart-Cussac, A.; Kala, S.; Espie, M.; et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001, 60 (4), 303-307.
9. Schmid, P.; Akrivakis, K.; Flath, B.; Grosse, Y.; Sezer, O.; Mergenrhaler, H.G.; Possinger, K. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-Cancer Drugs 1999, 10 (7), 625-631.
10. Valerio, M.R.; Cicero, G.; Armata, M.G.; Bajardi, E.; Crosta, A.; et al. In Gemcitabine (G) in Pretreated Breast Cancer (BC), Proceedings of the American Society of Clinical Oncology Annual Meeting, San Francisco, USA, May 12-15, 2001; American Society of Clinical Oncology: Alexandria, 2001; 51b.
11. Brodowicz, T.; Kostler, W.; Moslinger, R.; Tomek, S.; Vaclavik, I.; et al. Single agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 2000, 9 (6), 338-342.
12. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1959, 53, 457-481.
13. Cox, D.R. The Analysis of Binary Data; Methuen: London, 1970.
14. O'Shaughnessy, J.; Nag, S.; Calderillo-Ruiz, G.; Jordaan, J.; Llombart, A.; et al. In Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treuted metastatic breast cancer (MBC): interim results of a global phase III study, Proceedings of the American Society of Clinical Oncology Annual Meeting, Chicago, USA, May 31-Jun 3, 2003; American Society of Clinical Oncology: Alexandria, 2003; 7a.
15. Nabholtz, J.M.; Senn, H.J.; Bezwoda, W.R.; Melnychuk, D.; Deschenes, L.; et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J. Clin. Oncol. 1999, 17 (5), 1413-1424.
16. Sjostrom, J.; Blomqvist, C.; Mouridsen, H.; Pluzanska, A.; Ottosson-Lonn, S.; et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer 1999, 35 (8), 1194-1201.
17. Bonneterre, J.; Roche, H.; Monnier, A.; Guastalla, J.P.; Namer, M.; Fargeot, P.; Assadourian, S. Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br. J. Cancer 2002, 87 (11), 1210-1215.
18. O'Shaughnessy, J.; Miles, D.; Vukelja, S.; Moiseyenko, V.; Ayoub, J.P.; et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol. 2002, 20 (12), 2812-2823.
19. Holmes, F.A.; Walters, R.S.; Theriault, R.L.; Forman, A.D.; Newton, L.K.; et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer lnst. 1991, 83 (24), 1797-1805.
20. Holmes, F.A.; Valero, V.; Walters, R.S.; Theriault, R.L.; Booser, D.J.; et al. The M. D. Anderson Cancer Center experience with taxol in metastatic breast cancer. J. Natl. Cancer lnst. Monographs 1993, 15, 161-169.
21. Seidman, A.D.; Reichman, B.S.; Crown, J.P.; Yao, TJ.; et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol. 1995, 13 (5), 1152-1159.
22. Abrams, J.S.; Vena, D.A.; Baltz, J.; Adams, J.; Montello, M.; et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J. Clin. Oncol. 1995, 13 (8), 2056-2065.
23. Nabholtz, J.M.; Gelmon, K.; Bontenbal, M.; Spielmann, M.; Catimel, G.; et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 1996, 14 (6), 1858-1867.
24. Rinaldi, D.A.; Lormand, N.A.; Brierre, J.E.; Cole, J.L.; Stagg, M.P.; et al. Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2). Am. J. Clin. Oncol. 2002, 25 (5), 523-527.
25. Einhorn, L.; Raghavan, D.; Kindler, H.; Gordon, M.; Fox, S.; Meyers, T.; Sandler, A.A. In Phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors, Proceedings of the American Society of Clinical Oncology Annual Meeting, California, USA, May 16-19, 1998; American Society of Clinical Oncology: Alexandria, 1998; 207a.
26. Sanchez-Rovira, P.; Medina, M.B.; Mohendano, N.; Jaen, A.; Porras, I.; Gonzalez, E.; Fernandez, M.; Lozano, A. Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Ann. Oncol. 1998, 9 (Suppl. 4), 77.
27. Murad, A.M.; Guimaraes, R.C.; Aragao, B.C.; Scalabrini-Neto, A.O.; Rodrigues, V.H.; Garcia, R. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am. J. Clin. Oncol. 2001, 24 (3), 264-269.
28. Colomer, R.; Llombart-Cussac, A.; Lluch, A.; Barnadas, A.; Ojeda, B.; et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann. Oncol. 2004, 15 (2), 201-206.